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Background: Caldesmon (CaD), a major actin-associated protein, is found in smooth muscle and non-muscle cells.
Smooth muscle caldesmon, h-CaD, is a multifunctional protein, and non-muscle cell caldesmon, l-CaD, plays a role
in cytoskeletal architecture and dynamics. h-CaD is thought to be an useful marker for smooth muscle tumors, but
the role(s) of l-CaD has not been examined in tumors.
Methods: Primary colon cancer and liver metastasis tissues were obtained from colon cancer patients. Prior to
chemoradiotherapy (CRT), normal and cancerous tissues were obtained from rectal cancer patients. Whole-tissue
protein extracts were analyzed by 2-DE-based proteomics. Expression and phosphorylation level of main cellular
signaling proteins were determined by western blot analysis. Cell proliferation after CaD siRNA transfection was
monitored by MTT assay.
Results: The expression level of l-CaD was significantly increased in primary colon cancer and liver metastasis
tissues compared to the level in the corresponding normal tissues. In cancerous tissues obtained from the patients
showing poor response to CRT (Dworak grade 4), the expression of l-CaD was increased compared to that of good
response group (Dworak grade 1). In line with, l-CaD positive human colon cancer cell lines were more resistant to
5-fluorouracil (5-FU) and radiation treatment compared to l-CaD negative cell lines. Artificial suppression of l-CaD
increased susceptibility of colon cancer cells to 5-FU, and caused an increase of p21 and c-PARP, and a decrease of
NF-kB and p-mTOR expression.
Conclusion: Up-regulated expression of l-CaD may have a role for increasing metastatic property and decreasing
CRT susceptibility in colorectal cancer cells.Background
Caldesmon (CaD), a major actin-associated protein, is
found in smooth muscle cells (h-CaD; high molecular
weight, 89–93 kDa) and non-muscle cells (l-CaD; low
molecular weight, 59–63 kDa) [1,2]. At least two h-CaD
and four l-CaD isoforms are produced by alternative
splicing [3]. Smooth muscle caldesmon, h-CaD, is a
multifunctional protein which binds tightly and specifically
to actin, calmodulin, tropomyosin, and myosin [4-6]. It is
also a substrate for many protein kinases and is thought to
regulate cellular contraction [7].* Correspondence: yoo_akh@ncc.re.kr
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reproduction in any medium, provided the orThe expression of h-CaD is specific for smooth muscle
cells and soft tissue smooth muscle tumors, and in
contrast to other muscle markers, it is not expressed in
myofibroblasts or pericytes [8]. It was reported that h-CaD
is present only in smooth muscle tumors, among
various soft tissue tumors [9]. Thus, h-CaD is thought to
be an extremely useful marker for smooth muscle tumors
and has been used to identify soft tissue tumors with
myofibroblastic characteristics [10].
The cytoskeletal structure of endothelial cells regulates
their adhesive interactions with neighboring cells and
the extracellular matrix. These interactions in turn
control endothelial permeability and vessel wall integrity
[11,12]. In non-muscle cells, l-CaD plays a role in
cytoskeletal architecture and dynamics [13]. Although most
experimental data have been obtained using h-CaD, the
properties of l-CaD are expected to be quite similar [2,14].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the study participants
Sample no. Sex Age T N M CEA (ng/mL) Grade Location
CP1 F 55 4 2 1 4.3 Low S-colon
CP2 M 65 4 2 1 18.5 Low Rectum
CP3 F 34 3 0 0 0.7 Low S-colon
CP4 M 55 2 0 0 1.5 Low Rectum
CP5 F 66 3 1 1 33.7 Low S-colon
CP6 M 66 3 1 0 3.9 Low S-colon
CP7 F 66 3 1 1 33.7 Low S-colon
CP8 F 52 3 1 1 3.2 Low A-colon
CP9 M 51 4 2 1 14.9 Low S-colon
CP10 M 64 4 2 1 60.2 Low A-colon
CP11 F 64 3 0 1 50.7 Low Rectum
CP12 M 53 4 1 1 3.3 Low S-colon
CP13 F 46 4 1 1 9.3 Low A-colon
CP14 M 52 3 2 1 4.5 Low Rectum
CP15 F 58 3 2 1 145.4 Low S-colon
CP16 M 73 4 1 1 129.0 Low Rectum
RP17 F 65 3 1 0 26.9 Low Rectum
RP18 M 51 3 2 0 3.5 Low Rectum
RP19 M 53 3 1 0 0.8 Low Rectum
RP20 M 52 3 0 0 1.7 Low Rectum
RP25 F 70 4 2 0 5.4 Low Rectum
RP26 M 45 3 0 0 2.7 Low Rectum
RP27 M 70 3 2 0 10 Low Rectum
RP28 M 49 3 2 0 3.7 Low Rectum
RP33 M 59 3 1 0 12.5 Low Rectum
RP34 M 63 3 1 0 5.7 Low Rectum
RP35 F 38 4 1 0 1.9 Low Rectum
RP21 M 51 0 0 0 1.6 Low Rectum
RP22 M 56 0 0 0 4.3 Low Rectum
RP23 M 64 0 0 0 6 Low Rectum
RP24 M 72 0 0 0 3 Low Rectum
RP29 M 75 0 0 0 2.2 Low Rectum
RP30 F 42 0 0 0 1 Low Rectum
RP31 M 42 0 0 0 1.3 Low Rectum
RP32 M 55 0 0 0 2.6 Low Rectum
RP36 F 52 0 0 0 2.2 Low Rectum
RP37 F 63 0 0 0 2.5 Low Rectum
RP38 F 57 0 0 0 2.9 Low Rectum
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inclusion (Hela l-CaD) or exclusion (WI-38 l-CaD) of
exon 1. The results of a cohort study of cancers derived
from various organs, including colon and stomach,
suggested that Hela l-CaD could be used as a marker
for angiogenic endothelial cells during the early stages
of tumor neovascularization [15].
In a recent proteome assessment we found the clue that
aberrant expression of CaD isoforms in colon cancer may
link to tumor malignancy. We herein report altered expres-
sion of CaD in tissues from the patients with colon cancer,
and discuss its possible effects on tumor malignancy, such
as poor response to chemoradiation therapy.
Methods
Tissues from colorectal cancer patients
Fresh tissues (normal colon mucosa, primary colon
tumor, normal liver, and metastatic liver tumor) were
obtained from colon cancer patients who had synchronous
liver metastasis. After necrotic exudates and stromal
components were dissected, the overall cellularity of the
normal epithelium and tumors was more than 75%. Fresh
tissues (normal and cancerous) from rectal cancer patients
were also obtained prior to preoperative chemoradiother-
apy. Tumor regression grade was classified histologically
according to the regression system of Dworak [16] as
follows: grade 0, no regression; grade 1, minor regression
(dominant tumor mass with obvious fibrosis in ≤ 25%
of the tumor mass); grade 2, moderate regression
(dominant tumor mass with obvious fibrosis in 26–50%
of the tumor mass); grade 3, good regression (dominant
fibrosis outgrowing the tumor mass, i.e., > 50% tumor
regression); and grade 4, total regression (no viable tumor
cells, only fibrotic mass). Patient characteristics are
presented in Table 1. This study was approved and
conducted in accordance with the guidelines by the
Institutional Review Board of National Cancer Center,
Korea.
Two-dimensional gel electrophoresis, matrix-assisted laser
desorption/ionization mass spectrometry, and database
searching
Two-dimensional gel electrophoresis (2-DE) was performed
as described previously [17]. Briefly, samples (150 μg) of
proteins extracted from colon mucosa and colon tumor
tissues were applied to 13-cm immobilized pH 3–10 non-
linear gradient strips (Amersham, Uppsala, Sweden) and
focused at 8,000 V for 3 h. Second-dimension separation
was performed in 12% polyacrylamide gels (chemicals from
Serva, Heidelberg, Germany and Bio-Rad, Hercules, CA).
The 2-DE gels were stained with Colloidal Coomassie Blue
(Invitrogen, Carlsbad, CA) for 24 h and then destained with
deionized water. Images of the 2-DE gels were analyzed
using Melanie 4 software (Swiss Institute of Bioinformatics,Geneva, Switzerland). The 2-DE protein spots that
showed differential expression were subjected to matrix-
assisted laser desorption/ionization mass spectrometry
(MALDI-MS), performed as described previously [17].
Briefly, gel pieces containing proteins of interest were
excised, destained with 50% acetonitrile in 0.1 M ammo-
nium bicarbonate, and dried in a SpeedVac evaporator.
Dried gel pieces were rehydrated by incubation in 30 μl of
25 mM sodium bicarbonate, pH 8.8, containing 50 ng of
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α-Cyano-4-hydroxycinnamic acid (20 mg) (Bruker
Daltonics, Bremen, Germany) was dissolved in 1 ml of
acetone:ethanol (1:2, v/v), and 0.5 μl of the matrix solution
was mixed with an equivalent volume of sample. MALDI-
MS was performed using an Ultraflex TOF/TOF system
(Bruker Daltonics) operated in the positive ion reflection
mode. Each spectrum was the cumulative average of 250–
450 laser shots. Mass spectra were initially calibrated in
closed external mode using Peptide Calibration Standard II
(Bruker Daltonics) and sometimes in internal statistical
mode to achieve maximum calibration mass accuracy. The
spectra were analyzed using FlexAnalysis software, version
2.4 (Bruker Daltonics). Peptide mass peaks from each
spectrum were submitted for a Mascot peptide mass finger-
printing search (www.matrixscience.com) and analyzed
using BioTools software version 3.0 (Bruker Daltonics).
Searches included peaks with a signal-to-noise ratio > 3. To
identify proteins, the peak list for each sample was used to
query the non-redundant Mass Spectrometry Protein
Sequence Database. Standard settings included: enzyme
(trypsin), missed cleavage (one), fixed modifications (none
selected), variable modifications (oxidized methionine),
protein mass (blank), mass values (MH+, monoisotopic),
and mass tolerance (variable, 75 and 100 ppm).
Western blot analysis
Western blot analysis was performed using a standard
protocol [17]. Briefly, cell homogenates containing
equivalent amounts of protein were centrifuged at
4,000 × g, and the supernatant fractions were subjected
to SDS-PAGE. The separated proteins were transferred
to polyvinylidene fluoride membranes (Millipore,
Billerica, MA), which were blocked by incubation for
2 h at 4°C in 1% Tween 20-TBS buffer containing 1.5%
non-fat dry milk (Bio-Rad) and 1 mM MgCl2. Next, the
membranes were incubated with primary antibodies
against caldesmon (detecting both h-CaD and l-CaD)
(Abcam, Cambridge, UK), c-caspase-9 (Cell Signaling
Technology, Danvers, MA), c-PARP (Cell Signaling
Technology), p53 (Cell Signaling Technology), p21 (Cell
Signaling Technology), NF-κB (Cell Signaling Technology),
p-mTOR (Cell Signaling Technology), p-ERK (Cell
Signaling Technology), p-PI3K (Cell Signaling Technology),
p-AKT (Cell Signaling Technology) or β-actin (Abcam)
for 2 h at room temperature, washed for 3 × 15 min with
blocking solution, and then incubated with diluted
horseradish peroxidase-conjugated secondary antibody
(Southern Biotech, Birmingham, UK) for 1 h at room
temperature. After being washed with blocking solution
(3 × 15 min), the membranes were incubated with
WEST-ZOLW plus chemiluminescence reagent (iNtRON
Biotechnology, Gyeonggi, Korea) for 1 min and exposed
to film (Kodak Blue XB-1).Human colon cancer cell lines
Fourteen human colon cancer cell lines (SNU-81, SNU-
407, SNU-769A, SNU-769B, SNU-C4, SNU-C5, CaCo2,
DLD-1, HCT116, LoVo, NCI-H508, NCI-H747, SW480
and SW620) were obtained from the Korean Cell Line
Bank (Seoul, Korea) [18,19].
MTT assay
A colorimetric assay using the tetrazolium salt, MTT,
was used to assess cell proliferation after treatment with
5-FU or radiation. Equivalent numbers of cells (5 × 103
cells/well) were incubated in 0.2 ml culture medium in
each well. After 1, 2, 3 or 4 days of culture, 0.1 mg MTT
was added to each well, followed by incubation at 37°C
for a further 4 hr. Plates were centrifuged at 450 × g for
5 min at room temperature and the medium removed.
Dimethyl sulfoxide (0.15 ml) was added to each well to
solubilize crystals, and plates immediately read at 540 nm
using a scanning multiwell spectrometer (Bio-Tek instru-
ments Inc. Winooski, VT). Proliferation rate was obtained
from six biological replicates, and all experiments were
performed three times.
In vitro invasion assay
An in vitro invasion assay was performed using a kit
(Chemicon, Temecula, CA), according to the manufac-
turer’s protocol. Invasiveness was evaluated by staining cells
that had migrated through the extracellular matrix layer
and adhered to the polycarbonate membrane at the bottom
of the insert. Numbers of cells adhering to six different
regions of the bottom of the insert were counted at 200 ×
magnification.
Small interfering RNA synthesis and transfection
The target sequences used to generate siRNA (Qiagen,
Chatsworth, CA) were 50-CTGAGGGAGCCTCCCAAA
TAA-30 for l-CaD and 50-AATTCTCCGAACGTGTCA
CGT-30 for the non-silencing control. Transfection of
siRNA was performed using HiferFect transfection
reagent (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions. Briefly, 2 μl of 20 μM
siRNA solution and 20 μl transfection reagent were
incubated in 100 μl of serum-free RPMI 1640 medium
for 10 min to facilitate complex formation. The resulting
mixture (final concentration, 5 nM) was added to
SNU-C4, a human colon cancer cell line (4 × 105), and
incubated in a 60 mm tissue culture dish with 4 ml of
RPMI 1640.
Statistical analysis
Between-group differences were analyzed using the non-
parametric Mann–Whitney U test, and within-group
correlations were calculated using the Spearman rank
coefficient. Significance was set at P < 0.05.
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Differential expression of caldesmon between normal
colon mucosa samples and colon tumors obtained from
colorectal cancer patients
Whole-tissue protein extracts from colon mucosa samples
and colon tumors were analyzed by 2-DE (Figure 1a). A
protein spot with a molecular weight of 100 kDa and a pI
of 7.0 was expressed at a lower level in colon mucosa
tissues than in colon tumors (Figure 1a). The spot was
excised from the gel, digested with trypsin, and analyzed by
MALDI-MS to determine the peptide mass. A Swiss-Prot
database search identified the protein as caldesmon (CaD)
(Figure 1a, Additional file 1: Figure S1). Up-regulation of
caldesmon in colon tumor tissues was confirmed by
Western blot analysis (Figure 1b). The caldesmon protein
level was higher in colorectal cancer tissues compared with
the corresponding normal colon mucosa samples in six
colorectal cancer patients. Notably, the level of the 65 kDaFigure 1 A 2-DE-based comparative proteome analysis of normal colo
patients. (a) Typical 2-DE images of whole proteomes extracted from two
enlarged image was overexpressed in colon tumor tissues. MALDI-MS analy
identified it as caldesmon. (b) Differential expression of the 65 kDa isoform
l-CaD (65 kDa) were dominantly detected in tissues from colon cancer pati
significantly increased in colon tumors (T) compared with normal colon muisoform of caldesmon (l-CaD) was significantly higher
in colon tumor tissue than in normal colon mucosa
(Figure 1b).
Correlation between increased l-CaD levels in colorectal
cancers and in liver metastases
Western blot analysis of colorectal cancers and the
corresponding hepatic metastases revealed higher
expression of l-CaD (65 kDa) in the cancer tissues than
in normal colon mucosa (Figure 2a). Relative expression
levels of CaD in normal colorectal mucosa, colorectal
cancers, normal liver, and the corresponding liver metasta-
ses (n = 10 per group) were determined by normalization to
actin expression. For h-CaD (80 kDa), the mean relative
level showed no inter-group difference. In contrast, the
mean l-CaD level were significantly higher in both colorec-
tal cancers (P = 0.0115) and liver metastases (P = 0.0355)
compared with the levels in normal tissues (Figure 2b).n mucosa samples and colon tumors obtained from colon cancer
different tissues. The protein identified by the white arrow in the
sis of the protein highlighted in the upper panel unambiguously
of caldesmon (l-CaD). Two caldesmon isoforms, h-CaD (80 kDa) and
ents (CPs) by western blot analysis. The level of the l-CaD was
cosa (N).
Figure 2 Aberrant expression of l-CaD in primary tumors and liver metastases. (a) Expression pattern of l-CaD (65 kDa) among normal
colon mucosa, colon tumors, normal liver, and liver metastases. (b) Up-regulation of l-CaD in primary colon tumors and liver metastases. The two
isoforms were detected on western blots, and their relative expression levels were determined by normalization to actin. Although expression of
h-CaD (80 kDa) isoform did not differ among the sample groups, expression of l-CaD (65 kDa) was significantly increased in colon tumors
(P = 0.0115) and liver metastases (P = 0.0355) compared with normal colon mucosa samples.
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regression grade
The response to chemoradiotherapy was evaluated based
on the tumor regression grade, where grade 1 indicates a
poor response, and grade 4 is a complete response. In
Western blot analyses of 22 rectal cancer tissue samples,
l-CaD showed differential expression between tumors
with a poor response and those with a complete
response (Figure 3a). The expression levels of caldesmon
in the 22 rectal cancer tissues were normalized to actin
expression. The mean relative level of h-CaD expressiondid not differ between groups. Although l-CaD expression
tended to be higher in tumors with regression grade 4
compared with grade 1 tumors, the difference was not
statistically significant (P = 0.1713; Figure 3b).
Increased expression of l-CaD in human colon cancer cell
lines linked to 5-FU and radiation susceptibility
Expression level of CaD was also investigated in in
thirteen human colon cancer cell lines. Depending on a
cell type variable expression pattern of h-CaD was found
(Figure 4a). However, unlike in colon cancer tumor, l-CaD
Figure 3 Expression of l-CaD in rectal cancer patients according to chemoradiation response. (a) Expression pattern of l-CaD (65 kDa) in
tissues obtained from rectal cancer patients (RPs), according to Dworak tumor regression grade. Human HCT-116 and SNU-C4 colon cancer cells
were used as positive controls for the two caldesmon isoforms. (b) Differential expression of l-CaD (65 kDa) between Dworak tumor regression
grade 1 and 4 tumors. The two caldesmon isoforms were detected on Western blots, and their relative expression levels were determined by
normalization to actin. Expression of h-CaD (80 kDa) did not differ according to regression grade, whereas expression of l-CaD (65 kDa) was
slightly increased in Dworak tumor regression grade 4 tumors but did not reach statistical significance.
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including SNU-C5, CaCo2, HCT-116, SW480 and SW620
showed moderated expression of l-CaD (Figure 4a).
When cell lines were divided two groups, l-CaD
negative (SNU-C4, SNU-81, SNU-407, SNU-769A,
SNU-769B, DLD-1, LoVo, NCI-H508, NCI-H747) and
positive (SNU-C5, CaCo2, HCT-116 and SW620) cell
lines, relative poor response to 5-FU and radiation
was monitored in l-CaD positive cell lines (Figure 4b).
However, those differences were not statistically sig-
nificant, and expressional level of h-CaD was alsonot correlated either with 5-FU, radiation or invasion
(data not shown). To clarify whether l-CaD plays a
role for malignancy, the invasiveness and 5-FU or
radiation response of HCT-116 colon cancer cell line
with higher expression of l-CaD was investigated at
48 hr after artificial suppression of l-CaD by siRNA
transfection. 5-FU treatment after l-CaD suppression
increased 5-FU susceptibility in HCT-116 (Figure 4c),
but such artificial suppression of l-CaD did not change
the invasiveness and response to radiation in HCT-116
(data not shown).
Figure 4 Expressional relevance of l-CaD to 5-FU and radiation
response in human colon cancer cell lines. (a) Expression of
caldesmon isoforms in 14 human colon cancer cell lines. Unlike in
colon cancer tumor, most cell lines tested did not express l-CaD
(65 kDa). Moderated immunoreactive signal of l-CaD (65 kDa) was
detected only in SNU-C5, CaCo2, HCT-116, SW480 and SW620. (b)
Relative poor response of l-CaD (65 kDa) positive cell lines to 5-FU
and radiation. Expressional levels of h-CaD (80 kDa) isoforms were
correlated neither with 5-FU, radiation nor invasion (data not
shown). However, cell lines expressed l-CaD (65 kDa) (SNU-C5,
CaCo2, HCT-116, SW480, SW620) showed relatively poor response to
5-FU and radiation compared l-CaD (65 kDa) negative cell lines
(SNU-C4, SNU-81, SNU-407, SNU-769A, SNU-769B, DLD-1, LoVo,
NCI-H508, NCI-H747). (c) Effect of l-CaD (65 kDa) suppression on
5-FU. Treatment of 5-FU treatment after l-CaD siRNA transfection
increased 5-FU susceptibility in HCT-116. However, such artificial
suppression of l-CaD (65 kDa) did not alter the response to radiation
in HCT-116 (data not shown).
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of main cellular signaling molecules
Expression level of 9 major cell signaling molecules was
investigated at 48 hr after artificial suppression of l-CaD
by siRNA transfection. The l-CaD siRNA transfected cells
showed significantly higher expression levels of c-PARP
and p21 than the non-silencing siRNA transfected cells;
however, NF-kB and p-mTOR were decreased by the
transfection (Figure 5).
Discussion
Our recent 2-DE-based proteome approach showed that
caldesmon was expressed at higher levels in colon tumor
tissues than in normal colon mucosa samples (Figure 1).
Western blot analysis revealed that two isoforms of CaD,
h-CaD (80 kDa) and l-CaD (65 kDa) were dominantly
expressed in colon cancer tissues (Figure 1b). However,
only l-CaD was significantly higher in both colorectal
cancers (P = 0.0115) and liver metastases (P = 0.0355)
than in the corresponding normal mucosa samples
(Figure 2). Alternative splicing is a key mechanism for
creating complex proteomes from a relatively limited
number of genes. It has been estimated that about
three-quarters of all human genes undergo alternative
splicing [20-22], which may affect the function,
localization, binding properties, and stability of the
expressed proteins [23]. Alternative splicing can also
lead to transcript degradation, thereby abrogating
protein expression. For certain serine/arginine-rich
protein splicing factors, inclusion of a particular exon
causes mRNA degradation by nonsense-mediated
decay [24,25]. Tumor-specific CaD splice variants have
been reported in tissues from patients with colon,
urinary bladder, and prostate cancers [26]. In silico
protein predictions have suggested that tumor-specific
splice variants encode proteins with potentially altered
functions, indicating that they may be involved in
Figure 5 Effect of l-CaD silencing on expression of main cellular
signaling proteins. HCT-116 cells was transfeced by CaD siRNA, and
whole proteins was extracted at 48 hr after transfection to
investigate the expressional change of nine cellular signaling
molecules. The expression levels of c-PARP and p21 were increased
after l-CaD silencing, but NF-kB and p-mTOR were decreased
compared to the non-silencing siRNA transfected cells.
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targets [26]. Among the CaD isoforms, about 67 kDa
isoform of l-CaD is a major calmodulin-binding
protein present throughout the normal gastrointestinal
tract and in neoplastic human tissues [27]. Calmodulin
is a ubiquitous cytoplasmic protein that mediates many
actions of calcium in intestinal tissues, including the
regulation of growth and differentiation of normal and
neoplastic cells [27]. Significantly suppressed expression
of h-CaD and the actin-binding protein calponin h1 has
been reported in blood vessels of malignant melanomas
[28]. In malignant melanoma patients, the expression of
h-CaD was inversely correlated with the frequency of
metastasis and positively correlated with the survival
rate [28]. The suppression of h-CaD expression in the
blood vessels in malignant melanoma implies structuralfragility of the vessels, which could result in their easy
penetration by tumor cells. Defective expression of h-CaD
was therefore suggested as a marker for metastatic
potential and poor prognosis in melanoma [28]. Our
present results cannot clearly assign the role(s) of individual
CaD iosforms in colon cancer, but suggest that differential
expression of isoforms may be one of the causes leading to
tumor characteristics.
Interestingly, differential expression of l-CaD was also
monitored in the tissues from preoperative rectal cancer
patients (Figure 3). Higher expression of l-CaD was
found in tumors of regression grade 4, which indicates a
good chemotherapy response, than in regression grade 1
tumors, but the difference was not significant (P = 0.1713)
(Figure 3). Recent studies have shown that higher gene
expression of CaD, methylenetetrahydrofolate reductase,
and multidrug-resistance protein 1 was associated with a
response to chemotherapy in esophageal carcinoma [29,30].
Furthermore, our results showing the change of 5-FU
response in colon cancer cells by artificial suppression
of l-CaD strongly supports that l-CaD may play a role
for chemotherapy response (Figure 4c).
The phosphorylation of CaD by p34cdc2 kinase results in
dissociation of CaD from actin filaments and possibly plays
an important role in disassembly of actin cytoskeleton
during mitosis [31]. Therefore, the dysregulation of l-CaD
may lead to the change of proliferative characteristics in
cancer cells in response to radiation or anti-cancer drug
treatment. The l-CaD suppression in HCT-116 cells caused
up-regulation of c-PARP and p21 compared to the
non-suppressed cells (Figure 5). p21 as a CDK inhibitor 1
regulates cell cycle by inhibiting cyclin-CDK1 or 2
complexes [32], and also can induce cellular growth arrest
or apoptosis [33,34]. NF-KB is a “rapid-reacting” primary
transcription factor, and mTOR is also well-known protein
kinase involved in cell growth and proliferation [35,36].
Therefore, our l-CaD suppressed HCT-116 cells showed
characteristics similar to the cells under the apoptotic
process. The l-CaD siRNA transfected cells also showed
relatively high level of c-PARP, which is involved in DNA
repair [37]. However, if too much PARP is activated, PARP
can deplete cellular NAD+ and induce necrotic cell death
[37]. Thus, an increased level of c-PARP after l-CaD
suppression may represent the necrotic cell death as well.
Conclusions
Our overall data strongly support the positive link
between up-regulated expression of l-CaD and increased
malignancy of colorectal cancer. Dysregulated expression
of l-CaD may induce metastatic properties and change
CRT susceptibility in colorectal cancer cells. The expression
level of l-CaD may also be helpful in predicting the
response of upper gastrointestinal carcinomas to neoadju-
vant chemotherapy. However, the molecular mechanism by
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further verified.
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Figure 1a by MALDI-TOF analysis.
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